Search
Mitoquinone
go.drugbank.com/drugs/DB05063InvestigationalMitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … -- where they accumulate up to a thousand fold.
Cyanocobalamin Co-60
go.drugbank.com/drugs/DB09387ApprovedWithdrawnCyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.
EHT899
go.drugbank.com/drugs/DB05108ExperimentalEHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Tromantadine
go.drugbank.com/drugs/DB13288ApprovedTromantadine is marketed as Viru-Merz in the Czech Republic [L5740]. It is an antiviral used in the treatment of herpes zoster and simplex.
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the
RTP-801i
go.drugbank.com/drugs/DB06048InvestigationalRTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. … The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).
Cyclofenil
go.drugbank.com/drugs/DB13472ExperimentalCategories: Sex Hormones and Modulators of the Genital System, Selective Estrogen Receptor ModulatorsPhenoperidine
go.drugbank.com/drugs/DB13605ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCorticorelin
go.drugbank.com/drugs/DB05394InvestigationalCorticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.
NGX267
go.drugbank.com/drugs/DB05152InvestigationalIt is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.